Inflammatory myopathies

TRIM63 and Atrogin-1 are key drivers of systemic and muscle inflammation in patients with idiopathic inflammatory myopathies

Clin Exp RheumatolPublished Mechanistic study

Authors' conclusion

TRIM63 and Atrogin-1 are expressed in PBMC and muscle from patients with IIM and correlate with serum cytokines, and chemokines.

Study context

Population
Adult patients with idiopathic inflammatory myopathies (IIM) and age and sex-matched healthy donors
Participants
37 vs 10
Comparison
Adult IIM patients vs age and sex-matched healthy donors
  • IIMn = 37
  • Healthy donorsn = 10reference
Outcome
Expression of TRIM63 and Atrogin-1 (proportion of peripheral blood mononuclear cells (PBMC) subsets expressing them, serum and muscle levels) and relationship with inflammatory and atrophy parameters
Methodological detailsage and sex-matched healthy donors, multiparametric flow-cytometry, ELISA, luminometry, confocal microscopy
  • Age and sex-matched healthy donors
  • Multiparametric flow-cytometry
  • ELISA
  • Luminometry
  • Confocal microscopy

Main finding

As reported in the abstract

IIM
TRIM63+ CD4+ T cells 24.56 (7.71-53.23) vs. 2.55 (0.42-4.51); P < 0.0001
IIM
TRIM63+ CD8+ T cells 15.1 (3.22-37.40) vs. 1.06 (0.83-2.45); P = 0.0002
IIM
TRIM63+ monocytes 14.09 (3.25-29.80) vs. 1.97 (0.59-7.64); P = 0.011
IIM
Atrogin-1+ CD4+ T cells 27.30 (6.61-64.19) vs. 2.55 (0.42-4.51); P < 0.0001
IIM
Atrogin-1+ CD8+ T cells 14.88 (5.99-34.30) vs. 2.33 (0.60-8.01); P = 0.001
IIM
Atrogin1+ monocytes 17.38 (8.93-47.37) vs. 1.41 (0.79-3.77); P < 0.0001

Further findings

Muscle expression of TRIM63 and Atrogin-1

Muscle from IIM patients had a higher expression of TRIM63 and Atrogin-1

Correlation of TRIM63+ CD8+ T cells with serum cytokines

TRIM63+ CD8+ T cells mainly correlated with serum IL-2, IL-4, IL-8, IL-10, G-CSF, and TNF-a
  • Spearman Rho

Original publication

TRIM63 and Atrogin-1 are key drivers of systemic and muscle inflammation in patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol. Published 9 September 2024. doi:10.55563/clinexprheumatol/p2lma6

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.